Related Experiment Videos
Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement
C Castelo-Branco1, M J Martínez de Osaba, F Pons
1Department of Gynecology and Obstetrics, Hospital Clínic i Provincial, School of Medicine, University of Barcelona, Spain.
The Journal of Reproductive Medicine
|April 15, 1999
Summary
Adding ossein-hydroxyapatite compound (OHC) to hormone replacement therapy (HRT) significantly boosts bone mineral density in postmenopausal women. This combination therapy offers a superior approach to managing postmenopausal bone loss compared to either treatment alone.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Postmenopausal bone loss is a significant health concern.
- Hormone replacement therapy (HRT) is a common treatment for menopausal symptoms and bone loss.
- Ossein-hydroxyapatite compound (OHC) is a bone supplement.
Purpose of the Study:
- To investigate if combining OHC with HRT enhances the effects on postmenopausal bone loss.
- To compare the efficacy of HRT, OHC, and combined therapy on bone mineral density.
Main Methods:
- An open-label study involving 96 surgically postmenopausal women over one year.
- Four groups: HRT (estradiol), OHC, combined HRT-OHC, and untreated controls.
- Bone mass measured by dual x-ray absorptiometry; serum calcium, phosphate, and osteocalcin levels monitored.
Main Results:
- All treatment groups showed increased bone mineral content.
- The combined HRT-OHC group exhibited the greatest increase (4.7%, P < .01).
- Biochemical markers supported the observed bone mineral changes.
Conclusions:
- Combined HRT and OHC therapy significantly increased vertebral bone mass in postmenopausal women.
- This combination therapy is more effective than HRT or OHC alone.
- The OHC and HRT combination shows promise for managing postmenopausal bone loss.